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(57) ABSTRACT 
A polymer-coated cerium oxide based device and system is 
disclosed for detecting reactive oxygen species and monitor-
ing chronic inflammation. The device and system encapsulate 
free therapeutic nanoparticle elements not present in a living 
body in a prosthetic or implantable unit. Embodiment one is 
a two-chamber structure with a reactive oxygen species 
(ROS) scavenging component on one end and at the opposite 
end is an imaging agent consisting of at least one of a fluo-
rophore capable of fluorescence emission, a chemilumines-
cent agent, a magnetic relaxation agent and an X-ray contrast 
agent. Embodiment two is a single chamber device consisting 
of a multifunctional nanocomposite with a ROS-scavenging 
nanoparticle constituent ( nanoceria) and a multimodal report-
ing nanoparticle component (i.e. Dex-IO-DiR). The device 
and system are utilized in treatment of diseases with a pro-
inflammatory component, including, but not limited to, 
Crohn's disease, ulcerative colitis, inflammatory bowel dis-
ease, cystic fibrosis, arthritis, and cancer chemotherapy. 
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1 
CERIUM-OXIDE NANOPARTICLE BASED 
DEVICE FOR THE DETECTION OF 
REACTIVE OXYGEN SPECIES AND 
MONITORING OF CHRONIC 
INFLAMMATION 
GOVERNMENT LICENSE RIGHTS 
This invention was made with Government support under 
Agency contract number KOl CAlOl 781 and ROI 
GM084331 awarded by the National Institutes of Health. The 
government has certain rights in this invention. 
RELATED APPLICATIONS 
This invention claims the benefit of priority from U.S. 
Utility patent application Ser. No. 12/924,976 filed Oct. 8, 
2010 which claims the benefit of priority to U.S. Provisional 
Patent Application Ser. No. 61/250,750 filed Oct. 12, 2009. 
The entire disclosure of each of the applications listed in this 
paragraph are incorporated herein by specific reference 
thereto. 
FIELD OF THE INVENTION 
This invention relates to uses of nanoceria particles, and in 
particular to nanoceria-based methods, systems aid devices 
useful in detecting reactive oxygen species and monitoring 
chronic inflarmnation in vivo. 
BACKGROUND AND PRIOR ART 
Most recently, it has been found that nanosized cerium 
oxide (nanoceria) possesses antioxidant activity at physi-
ological pH and has potential use in biomedical applications, 
such as protection against radiation damage, oxidative stress 
and inflammation, as reported by various researchers, includ-
ing R. W. Tamuzzer, et al. in Nano Lett 2005, 5, 2573; J. P. 
Chen, eta!. inNature Nanotechnology 2006, 1, 142; J. Niu, et 
al in Cardiovasc Res 2007, 73, 549; M. Das, et al. in Bioma-
terials 2007, 28, 1918 and J. M. Perez, et al. in Small 2008. 
Biological systems have evolved to utilize readily available 
elements, such as carbon, oxygen, hydrogen, nitrogen, cal-
cium and iron. Less abundant elements may be utilized as 
co-factors in enzymatic complex factors, or can be found in 
chelated forms surrounded by aromatic rings and coordinated 
bonding. However, many elements, including rare earths, 
such as cerium, are not present in living organisms, due to 
their highly reactive nature resulting in toxicity. 
2 
dephosphorylation of phosphopeptides by cerium oxide" J 
Mass Spectrom, 2008. 43(5): 628-632 and Xia, T., et al. in 
"Comparison of the mechanism of toxicity of zinc oxide and 
cerium oxide nanoparticles based on dissolution and oxida-
tive stress properties" ACS Nano, 2008. 2(10): 2121-2134. 
Furthermore, Asati, A., et al. in "Oxidase-Like Activity of 
Polymer-Coated Cerium Oxide Nanoparticles" Angew Chem 
Int Ed Engl, 2009 reported the oxidase-like activity of these 
nanoparticles in acidic microenvironments, which may facili-
10 tate the oxidation of intracellular and extracellular compo-
nents. Most importantly, as cerium is not found in the human 
body and there are no clearance mechanisms for it, cerium 
may cause toxicity, contrary to iron oxide nanoparticles, 
where the iron-containing core can be metabolized and 
15 uptaken by ferritin and transferrin, as reported by Xia, T., et 
al. in "Comparison of the mechanism of toxicity of zinc oxide 
and cerium oxide nanoparticles based on dissolution and 
oxidative stress properties" ACS Nano, 2008, supra and Rzi-
galinski, B. A., "Nanoparticles and cell longevity" Technol 
20 Cancer Res Treat, 2005 4(6): 651-659. 
In view of the above findings, potential in vivo application 
of these nanoparticles has been limited. The prior art in the 
applications of nanoceria pertains to the administration and 
use of the nanoparticles free in solution, hence nanoparticle 
25 clearance and toxicity may be observed. No prior art reports 
the encasing of these nanoparticles in a device, such as 
described in the present invention, thereby preventing direct 
exposure of the living organism to these nanoparticles. 
Thus, a device encapsulating therapeutic elements not 
30 present in a living body, such as cerium oxide, is an attractive 
alternative, preventing the adverse side effects from free 
nanoparticles in circulation. Therefore, for these reasons, it 
would be advantageous to introduce nanoparticles within 
devices to minimize their exposure, accumulation and poten-
35 tial toxicity to biological systems. Such an embodiment 
would be classified as a prosthetic (implantable) device and 
not a drug, expediting the adoption of these nanoparticles in 
therapy and the clinic. 
It is desirable to extend the utility of the coated nanoceria 
40 particles as a stable, effective, therapeutic device, system or 
method for detecting reactive oxygen species and monitoring 
chronic inflammation in biological tissue, while causing no 
adverse side effects or toxicity to the body. The present inven-
tion provides a much needed weapon in the arsenal for treat-
45 ing a broad range of ailments with a pro-inflammatory com-
ponent, for cancer therapy, for patients with transplants or 
prosthetic devices and the like. 
SUMMARY OF THE INVENTION 
Hence, cells do not have protective apparatuses against 50 
elements not present in living organisms, and organisms do 
not have mechanisms to handle the storage, utilization and 
release of these elements from the body. For instance, lead 
and arsenic accumulate in the body and can lead to severe 
pathological conditions, including organ failure and death. 55 
Also, nanoparticles composed of metals such as cadmium in 
Quantum dots (QDOTS) are partially toxic. 
A primary objective of the present invention is to provide a 
device, system and method encapsulating therapeutic ele-
ments not present in a living body, such as cerium oxide 
nanoparticles, in a prosthetic or implantable unit thereby pre-
venting adverse side effects from free nanoparticles in circu-
lation. 
A secondary objective of the present invention is to provide 
a cerium oxide nanoparticle-based device, system and 
method for the detection ofreactive oxygen species (ROS). 
Similarly, cerium oxide nanoparticles, despite being potent 
reactive oxygen species (ROS) scavengers and selective cyto-
protective agents, have shown cellular uptake and intracellu- 60 
lar residency of cerium oxide nanoparticles which induces 
dephosphorylation of various substrates, causing aberrant 
cell signaling and alterations in the transcriptional and post-
translational levels, as reported by J. M. Perez et al. in "Syn-
thesis of biocompatible dextran-coated nanoceria with pH- 65 
dependent antioxidant properties" Small, 2008. 4(5): 552-
556, Tan, F., et al. in "An efficient method for 
A third objective of the present invention is to provide a 
cerium oxide nanoparticle-based system, method and device 
for monitoring chronic inflammation. 
A fourth objective of the present invention is to provide a 
cerium oxide nanoparticle-based system, method and device 
for the detection ofreactive oxygen species (ROS) and moni-
toring of chronic inflammation, through the co-encasing of 
cerium oxide and fluorescent polymeric iron oxide nanopar-
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ticles (including Dex-IO-DiR and PAA-IO-DiI) in a two-
chamber biocompatible device utilizing the potent ROS scav-
enging activity of cerium oxide nanoparticles. 
A fifth objective of the present invention is to provide a 
cerium oxide nanoparticle-based system, method and device 
for the detection of reactive oxygen species (ROS) and moni-
toring of chronic inflammation, through the interspersing of 
cerium oxide and fluorescent polymeric iron oxide nanopar-
ticles (including Dex-IO-DiR and PAA-IO-DiI) in a single 
chamber biocompatible device utilizing the potent ROS scav- 10 
enging activity of cerium oxide nanoparticles. 
A sixth objective of the present invention is to provide a 
stable, effective, cerium oxide nanoparticle-based therapeu-
tic device, system and method for detecting reactive oxygen 15 
species and monitoring chronic inflammation in biological 
tissue, while causing no adverse side effects or toxicity to the 
body. 
A seventh objective of the present invention is to provide 
monitoring ofinflammation levels by changes in fluorescence 20 
emission (increase or decrease in the signal measured via 
optical methods), changes in magnetic relaxation (increase or 
decrease in the signal assessed via MRI), or alterations in 
other modalities' properties such as, X-ray contrast). 
4 
The preferred imaging agent is a hydrophobic fluorophore 
selected from at least one of octodecyl indocarbocyanine 
(DiI), indodicarbocyanine (DiD) and indotricarbocyanine 
(DiR) encapsulated within the plurality of polymeric cavities 
of the polymer-coated nanoparticle selected from at least one 
of iron oxide, bismuth, europium, gadolinium and chelates 
thereof, coated with dextran, PAA, HBPE, PLGA, and mix-
tures thereof. 
It is also preferred that the imaging agent in the second 
chamber is a hydrophilic fluorophore selected from at least 
one of cyanine 5.5 (Cy5.5) and ICG encapsulated within the 
plurality of polymeric cavities of the polymer-coated nano-
particle of iron oxide, bismuth, europium, gadolinium and 
chelates thereof, coated with dextran, PAA, HBPE, PLGA, 
and mixtures thereof. 
It is further preferred that the polymer-coated nanopar-
ticles of iron oxide are coated with polymers selected from 
dextran and polyacrylic acid that are used to monitor reactive 
oxygen species generation through magnetic resonance 
imaging (MRI). The polymer-coated nanoparticles of iron 
oxide are also used to monitor inflammation and upregulated 
reactive oxygen species (ROS) production through fluores-
cence-based optical methods. 
The reactive oxygen species (ROS) scavenging component 
of the preferred device protects the imaging agent from expo-
sure to ultraviolet (UV) radiation. 
A second embodiment of a preferred device encapsulates 
free therapeutic nanoparticle elements not present in a living 
body in a prosthetic or implantable unit having a single cham-
ber containing a reactive oxygen species (ROS) scavenging 
component interspersed with an imaging agent in a prese-
lected ratio of 1:1, 1:2 and 2:1, whereby the scavenging 
component and the imaging component simultaneously com-
municate with an aqueous environment through the exterior 
semi-permeable membrane of the single chamber allowing 
the diffusion of ROS from the environment on the exterior of 
the chamber such that the device can sense elevated non-
physiological reactive oxygen species (ROS) levels associ-
A preferred device of the present invention encapsulates 25 
free therapeutic nanoparticle elements not present in a living 
body in a prosthetic or implantable unit having a first chamber 
for a reactive oxygen species (ROS) scavenging component 
having an exterior semi-permeable membrane surface and an 
interior cavity containing the ROS scavenging component, a 30 
second chamber for an imaging agent having an exterior 
semi-permeable membrane surface and interior cavity con-
taining the imaging agent, and the first chamber and the 
second chamber joined in a non-communicating marmer so 
that both the first chamber and the second chamber indepen- 35 
dently communicate with an aqueous environment through 
the exterior semi-permeable membrane of each chamber 
allowing the diffusion of ROS from the environment on the 
exterior of the first chamber and the exterior of the second 
chamber such that the device can sense elevated non-physi-
ological reactive oxygen species (ROS) levels associated with 
40 ated with at least one of the following conditions, inflamma-
tion, exposure to radiation and changes in a cellular micro-
environment; thereby forming a single chamber device 
consisting of a nanocomposite, derived from the conjugation 
and linking of polymer-coated nanoceria with at least one of 
at least one of the following conditions, inflammation, expo-
sure to radiation, and changes in a tissue/cellular micro-en-
vironment. 
In the preferred device, the ROS-scavenging component in 
the first chamber is a plurality of nanoparticles selected from 
45 the following nanoparticles, Dex-IO-DiR, PAA-IO-DiR and 
mixtures thereof. 
at least one of a polymer-coated cerium oxide that is coated 
with at least one of dextran and polyacrylic acid, and poly-
meric nanoparticles encapsulating a "soft" ROS-scavenging 
agent, selected from at least one of polymeric nanoparticles 50 
encapsulating proteins, polymeric nanoparticles encapsulat-
ing chemicals and polymeric nanoparticles encapsulating a 
small molecule. 
It is preferred that the protein encapsulated by polymeric 
nanoparticles is selected from at least one of catalase, super- 55 
oxide dismutase and the chemical encapsulated by polymeric 
nanoparticles is peroxidase and the small molecule encapsu-
lated by polymeric nanoparticles is reduced glutathione. 
In the preferred device, the second chamber contains an 
imaging agent selected from at least one of a fluorophore 60 
capable of fluorescence emission, a chemiluminescent agent, 
a magnetic relaxation agent and an X-ray contrast agent 
encapsulated within a plurality of polymeric cavities in a 
polymer-coated nanoparticle selected from at least one ofiron 
oxide, bismuth, europium, gadolinium and chelates thereof, 65 
coated with dextran, PAA, HBPE, PLGA, and mixtures 
thereof. 
It is preferred that the ROS scavenging component in the 
single chamber is a plurality of nanoparticles selected from a 
polymer-coated cerium oxide coated with at least one of 
dextran and polyacrylic acid, and polymeric nanoparticles 
encapsulating a "soft" ROS-scavenging agent, selected from 
at least one of polymeric nanoparticles encapsulating pro-
teins, polymeric nanoparticles encapsulating chemicals and 
polymeric nanoparticles encapsulating a small molecule. 
It is also preferred that the protein encapsulated by poly-
meric nanoparticles is selected from at least one of catalase, 
superoxide dismutase and the chemical encapsulated by poly-
meric nanoparticles is peroxidase and the small molecule 
encapsulated by polymeric nanoparticles is reduced glu-
tathione. 
The preferred imaging agent in the single chamber is 
selected from a fluorophore capable of fluorescence emis-
sion, a chemiluminescent agent, a magnetic relaxation agent 
and an X-ray contrast agent encapsulated within a plurality of 
polymeric cavities in a polymer-coated nanoparticle selected 
from at least one of iron oxide, bismuth, gadolinium, chelates 
of gadolinium and europium. 
US 8,795,733 Bl 
5 
The imaging agent is a hydrophobic fluorophore selected 
from at least one of octodecyl indocarbocyanine (DiI), 
indodicarbocyanine (DiD) and indotricarbocyanine (DiR) 
encapsulated within the plurality of polymeric cavities of the 
polymer-coated nanoparticle selected from at least one ofiron 
oxide, bismuth, gadolinium, chelates of gadolinium and 
europium. 
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FIG. 2 is a schematic representation of the operation prin-
ciple of the in vivo inflammation monitoring device of the 
present invention. 
FIG. 3 is a graph of the time-dependent fluorescence of the 
nanoparticles (HBPE-DiI) in the presence of reactive oxygen 
species (ROS). 
FIG. 4 is a graph showing the decrease in the fluorescence 
emission of nanoparticles after 24 hours in the presence of 
hydrogen peroxide (H2 0 2). 
FIG. 5 is a graph of time-dependent nanoparticle fluores-
cence emission in the presence of nanoceria and ROS in 
suspension. 
It is most preferred that the imaging agent in the single 
chamber is a hydrophilic fluorophore selected from at least 
one of cyanine 5.5 (Cy5.5) and indocyanine green (ICG) 10 
encapsulated within the plurality of polymeric cavities of the 
polymer-coated nanoparticle of iron oxide, europium, bis-
muth, gadolinium, chelates of gadolinium, and mixtures 
thereof. 
FIG. 6 is a graph of fluorescence intensity of nanoceria 
particles in water and in H2 0 2 showing that nanoceria pro-
15 vides sustained protection from ROS to fluorescent nanopar-
ticles. 
The polymer-coated nanoparticles of iron oxide are coated 
with polymers selected from dextran and polyacrylic acid are 
used to monitor reactive oxygen species generation through 
magnetic resonance imaging (MRI) and are also used to 
monitor inflanimation and upregulated reactive oxygen spe-
cies (ROS) production through fluorescence-based optical 20 
methods. 
FIG. 7 is a graph of time-dependent retention of the fluo-
rescence emission of fluorescent nanoparticles (HBPE-DiI) 
by nanoceria after exposure to ultraviolet (UV) radiation. 
FIG. SA shows a cerium oxide nanoparticle-based device 
wherein the fluorescence emission of the DiI-Dex-IO nano-
particles is stable under physiological conditions (no ROS 
i.e., no H2 0 2 , pH 7) as determined after 24 hour incubation. 
The reactive oxygen species (ROS) scavenging component 
of the single chamber device protects the imaging agent from 
exposure to ultraviolet (UV) radiation. 
A preferred nanocomposite system encapsulating free 
therapeutic nanoparticle elements not present in a living body 
requires the preparation of a miniature device containing a 
reactive oxygen species (ROS) scavenging agent and a fluo-
rophore imaging agent, implanting the miniature device in a 
physiological environment, exposing the miniature device to 
non-physiological ROS levels, andmonitoringthe near-infra-
red fluorophore changes and magnetic relaxation time shifts, 
signaling the abnormal ROS concentration. 
The preferred nanocomposite system further consisting of 
a miniature device, that is exposed to elevated ROS levels and 
prevents the regeneration of the ROS scavenger, leading to 
multimodal sensing changes in fluorescence emission and an 
increase in the magnetic relaxation (MRI) times of the nano-
composite. 
The preferred nanocomposite system further comprising 
multimodal tracking, having as components nanoparticles 
with chemiluminescence, magnetic relaxation or X-ray con-
trast agents. 
The preferred nanocomposite system is transplantable as a 
distinct entity or part of a prosthetic device and is utilized in 
diseases with a pro-inflanimatory component selected from 
the group consisting of, Crohn's disease, ulcerative colitis, 
inflammatory bowel disease, cystic fibrosis, and arthritis. 
FIG. SB shows a cerium oxide nanoparticle-based device 
25 wherein the fluorescence emission of the DiI-Dex-IO nano-
particles is diminished after 24-hour-long exposure to ROS 
(H2 0 2 , pH 7). 
FIG. SC shows that a cerium oxide nanoparticle-based 
device with polymer-coated, polyacrylic acid (PAA), nanoc-
30 eria does not affect the fluorescence emission of the DiI-Dex-
IO nanoparticles after 24-hour-long incubation at physiologi-
cal conditions (no ROS i.e., no H2 0 2 , pH 7) 
FIG. SD shows that a cerium oxide nanoparticle-based 
device with polymer-coated, polyacrylic acid (PAA), nanoc-
35 eria does not affect the fluorescence emission of the DiI-Dex-
IO nanoparticles from ROS after 24-hourexposure to H2 0 2 at 
pH7. 
FIGS. 9A, 9B, 9C shows that a cerium oxide nanoparticle-
based device with polymer-coated, polyacrylic acid (PAA), 
40 nanoceria protects the fluorescence emission of the DiI-Dex-
IO nanoparticles from ROS for a period of24 hours at physi-
ological H2 0 2 concentrations of0.5 µM, 1.5 µMand 3.0 µM 
in solutions with a pH value of 7. 
FIG. lOA shows that a cerium oxide nanoparticle-based 
45 device with polymer-coated, polyacrylic acid (PAA), nanoc-
eria does not protect the fluorescence emission of the DiI-
Dex-IO nanoparticles from ROS for a period of24 hours at a 
non-physiological pH value of 4 in the presence of H20 2 , 
The nanocomposite system has a miniature device that is 
also utilized in a treatment regime monitoring the potential 50 
induction of inflammation in at least one of cancer chemo-
therapy and antimicrobial therapy and also in real-time moni-
toring of ROS during the synthesis of ROS-sensitive com-
pounds. 
allowing imaging of ROS generation. 
FIG. lOB shows that a cerium oxide nanoparticle-based 
device with polymer-coated, polyacrylic acid (PAA), nanoc-
eria does not protect the fluorescence emission of the DiI-
Dex-IO nanoparticles from ROS for a period of 24 hours 
during inflammatory conditions and the presence of H20 2 , 
The preferred nanocomposite system is also used in tissue 
protection against elevated ROS levels, in chemotherapy, 
prosthesis, and post-transplant operations. 
55 allowing imaging of ROS generation. 
FIG. 11 is a graph showing the percent change in fluores-
cent intensity of a cerium oxide nanoparticle-based device 
with polymer-coated, polyacrylic acid (PAA), nanoceria 
wherein the fluorescence emission of the DiI-Dex-IO nano-
Further objects and advantages of the present invention 
will be apparent from the following detailed description of a 
presently preferred embodiment, which is illustrated sche-
matically in the accompanying drawings. 
60 particles changes with H2 0 2 concentrations of 0.5 µM, 1.5 
µM, 3.0 µM, 1.0 µMat pH value 4 and 6.0 µM. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a conceptual diagram of the in vivo inflanimation 65 
monitoring device of the present invention having two non-
communicating chambers. 
FIG. 12 is a graph of the stability of the non-encapsulated 
fluorophore (DiI) at physiological and acidic pH values, pH 
7 .5 and pH 4, respectively. 
FIG. 13 is a graph of the fluorescence emission stability of 
the non-encapsulated fluorophore (DiI) at physiological and 
acidic pH values, pH 7 .5 and pH 4, respectively 
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FIG. 14 is a chart showing the regeneration capacity of 
polymer-coated, polyacrylic acid (PAA), nanoceria at pH 7; 
atpH7and1.0µMH 2 0 2 ; atpH4and1.0 µMH 20 2 ; and at pH 
7 and 6.0 µM H20 2 ; at low pH or high inflammation the 
nanoceria component cannot regenerate after exposure to 5 
reactive oxygen species (ROS). 
FIG. 15 is a schematic depiction of the detection of ROS 
with a device consisting of a nanoceria ROS-scavenging 
chamber and a multimodal DiR-Dex-IO nanoparticle (NIR-
fluorescent/MRI) monitoring chamber. 10 
FIG. 16A shows that a cerium oxide nanoparticle-based 
device with no polyacrylic acid (PAA) coated nanoceria and 
with multimodal DiR-Dex-IO nanoparticles is sensitive 
towards ROS generated by H2 0 2 (1.0 µM), after 24-hour 15 
exposure to H20 2 in pH 7 (physiological pH). The ROS 
beacons are multimodal and can sense ROS via changes in 
fluorescence and T2 relaxation times (T2,n = 165 ms, 
T2fin =280 ms). 
FIG. 16B shows that a cerium oxide nanoparticle-based 20 
device with both polymer-coated, polyacrylic acid (PAA) 
nanoceria and multimodal DiR-Dex-IO nanoparticles can 
differentiate physiological ROS levels generated by H2 0 2 (1 
µM), after 24-hour exposure to H20 2 in pH 7 (physiological 
pH). At physiological pH and ROS levels, the ROS beacons 25 
retain their fluorescence emission intensity and a small 
change in the T2 relaxation times are observed (T2,n =165 ms, 
T2fin =220 ms). 
FIG. 17A shows the clustering that is observed in the 
multimodal DiR-Dex-IO nanoparticles upon incubation 30 
without ROS, i.e., H2 0 2 . 
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Chemical names for fluorophores: 
DiI-1, 1 '-dioctadecyl-3,3,3' ,3'-tetramethylindocarbocya-
nine perchlorate 
DiD-1, 1 '-dioctadecyl-3,3,3' ,3'-tetramethylindodicar-
bocyanine perchlorate 
DiR-1, 1 '-dioctadecyl-3,3,3' ,3'-tetramethylindotricar-
bocyanine iodide 
ICG-indocyanine green (lH-Benz[e]indolium, 2-[7-[1, 
l-dimethyl-3-( 4-sulfobutyl)benz[ e ]indolin-2-ylidene ]-1,3, 
5-heptatrienyl]-1, l-dimethyl-3-( 4-sulfobutyl)-, hydroxide) 
Cy5.5--cyanine 5.5 
Dex-IO-DiR is an abbreviation used herein to mean dext-
ran-coated iron oxide with indotricarbocyanine (DiR) encap-
sulated in the polymeric dextran coating. 
GSNO is an acronym for N-(N-L-y-glutamyl-5-nitroso-
L-cysteinyl)-glycine 
HBPE-DiI is an abbreviation used herein to mean hyper-
branched polyester nanoparticles encapsulating indocar-
bocyanine (DiI). 
MRI is an acronym for magnetic resonance imaging. 
PAA is the acronym used herein to mean polyacrylic acid. 
PAA-IO-DiI is an abbreviation used herein to mean poly-
acrylic acid-coated iron oxide nanoparticles encapsulating 
indocarbocyanine (DiI). 
PLGA is the acronym used herein to mean Poly-Lactic-
Co-Glycolic Acid. 
"Physiological" is a term used herein to mean a character-
istic of or appropriate to an organism's healthy or normal 
functioning which is measured by such factors as pH value, 
inflammation levels and the like. For example, the normal pH 
range of the intracellular fluid of cells is 6.9-7.4. One of the 
most important processes in the human body is the process by 
which the pH balance is maintained. Body pH measures the 
number of hydrogen ions in solution within the body. The pH 
FIG. 17B shows the clustering that is observed in the mul-
timodal DiR-Dex-IO nanoparticles upon incubation with 
ROS, i.e., H20 2 . 
FIG. 18 shows the corresponding change in T2 relaxation 
signal (MRI signal) upon addition ofH2 0 2 . 
35 scale ranges from 0-14 with <6.4 acidic and >6.4 alkaline for 
body fluid, not including blood which is a normal 7 .3 pH. An 
acidic pH has a low ability to attract hydrogen ions, while an 
alkaline solution has a high ability to attract hydrogen ions. FIG.19 is a conceptual diagram of the in vivo inflanmiation 
monitoring device of the present invention having a single 
chamber, which also shows the cross-sectional view of the 40 
device's fluorescence and MRI response to physiological and 
non-physiological conditions. 
FIG. 20 is a side-view of the fluorescence image of the 
single-chamber device consisting of polymer-coated, poly-
acrylic acid (PAA) nanoceria and DiR-Dex-IO nanoparticles 45 
after 24-hour-long incubation at physiological conditions (1: 
no ROS i.e. no H2 0 2 , pH 7), at a physiological H2 0 2 concen-
tration (2: 1 µM H2 0 2 , pH 7), at a non-physiological inflam-
matory H20 2 concentration (3: 6 µM H20 2 , pH 7), and at a 
non-physiological chronic inflammatory H20 2 concentration 50 
and non-physiological pH (4: 6 µM H2 0 2 , pH 4). 
FIG. 21 is a top-view of an MRI image of the single-
chamber consisting of polymer-coated, polyacrylic acid 
(PAA) nanoceria and DiR-Dex-IO nanoparticles after 
24-hour-long incubation at physiological (1: no ROS i.e. no 55 
H2 0 2 , pH 7; 2: 1 µM H2 0 2 , pH 7) or non-physiological 
conditions (3: 6 µM H20 2 , pH 7; 4: 6 µM H20 2 , pH 4). 
"p" stands for potential and "H" stands for hydrogen; hence-
forth, the potential of the body to attract hydrogen ions to 
secure balance and health. 
ROS is an acronym for reactive oxygen species and for the 
research purposes herein hydrogen peroxide (H2 0 2 ) is used 
as a representative ROS chemical reagent. 
The term "nanoceria" is used interchangeably with 
"cerium oxide nanoparticles" and is used to refer to the 
cerium oxide particles of multiple valences (Ce+3/Ce+4 ). 
The present invention is capable of several embodiments 
which include a reactive oxygen species (ROS) scavenging 
agent, an imaging agent and multiple methods for the conju-
gation of the scavenging agent and imaging agent in a nano-
composite device, as discussed in more detail below. 
ROS Scavenging Agent: 
The ROS scavenging agent used in the device consists of 
polymer-coated cerium oxide nanoparticles which have high 
antioxidant/free radical scavenging activity. The nanopar-
ticles can be prepared using different synthetic protocols, 
including water-based formulations. At normal pH 7 nanoc-
eria can effectively sequester ROS generated from various DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
60 sources, including UV radiation, inflanmiation and chemical 
decomposition, as occurs with H2 0 2 and GSNO(S-nitroso-
L-glutathione ), due to the reversible switch from Ce+3 and 
Ce+4 states. This property renders cerium oxide an ideal ROS-
scavenging agent. Moreover, at non-physiological pH or 
65 likely under conditions of enhanced ROS generation, nanoc-
eria is not able to perform the autocatalytic reversible switch-
ing between its two valence states. This allows nanoceria to 
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serve as a binary switch (ON/OFF) for aberrant ROS produc-
tion. Apart from nanoceria, other ROS scavenging agents can 
be used, including "soft" ROS scavenging agents such as 
polymeric nanoparticles encapsulating proteins or chemicals, 
including, but not limited to, catalase, superoxide dismutase, 
peroxidase, and glutathione. "Soft" is used herein to mean 
non-metallic. Examples of"soft" or non-metallic ROC agents 
include, but are not limited to, polymeric nanoparticles 
encapsulating proteins, polymeric nanoparticles encapsulat-
ing chemicals such as, catalase, superoxide dismutase, per- 10 
oxidase and small molecules, such as, reduced glutathione. 
Imaging Agent: 
The imaging agent consists of multimodal polymer-coated 
iron oxide nanoparticles, due to the nanoparticles' enhanced 
magnetic properties and FDA approval as clinical imaging 15 
agents for MRI. The polymer-coated iron oxide nanoparticles 
can be synthesized using diverse protocols, including the 
water-based alkaline precipitation method. Effective doping 
of the nanoparticles with a fluorophore can be achieved via 
different methodologies, such as the water diffusion proce- 20 
dure or via direct chemical conjugation. Apart from iron 
oxide nanoparticles, nanoparticles with gadolinium/gado-
linium chelates, bismuth, Qdots, and europium can be used. A 
fluorophore, a conductive polymer or a fluorophore-polymer 
conjugate that is sensitive to ROS can serve as an imaging 25 
agent of ROS. Furthermore, imaging of ROS can be achieved 
via changes in the relaxation times of the nanoparticle solu-
tion (in the case of iron oxide T2). 
Multimodal Nanocomposite: 
The multifunctional and multimodal nanocomposite can 30 
be created by the conjugation of a ROS sensing nanoparticle 
formulation with an imaging nanoparticle preparation. Effi-
cient nanocomposite formation can be achieved using various 
chemistries, including carbodiimide for aminated and car-
boxylated nanoparticles, or "click" chemistry for azide-pro- 35 
pargylated nanoparticles. Hence for instance, the nanocom-
posite can be obtained by the "click" conjugation of 
propargylated PAA-coated nanoceria and azide-carrying 
DiR-PAA-IO, or carbodiimide conjugation of PAA-coated 
nanoceria and aminated DiR-Dex-IO. Overall though, either 40 
constituent of the nanocomposite can be of "soft" or "hard" 
nanoparticles. Specifically, "soft" pertains to polymeric 
nanoparticles encapsulating a ROS scavenging agent of non-
metallic nature (i.e. small molecule, protein) or an imaging 
agent entrapped within polymeric microdomains and cavities 45 
(i.e. fluorophore, chelated ions). On the other hand, "hard" 
nanoparticles include metallic nanoparticles, such as the ROS 
sensing polymer-coated nanoceria, polymer-coated iron 
oxide, and Quantum dots. 
In the present invention, the cerium oxide nanoparticles or 50 
nanoceria are used in a biocompatible device forthe detection 
of reactive oxygen species (ROS) and monitoring of chronic 
inflammation through the co-encasing of cerium oxide and 
fluorescent polymeric iron oxide nanoparticles, in an exem-
plary embodiment. Nanoparticle sizes are provided as an 55 
example, not for limitation of the invention. PAA-coated 
nanoceria can have particles that are approximately 6-8 
nanometers (nm) in diameter; Dextran-coated nanoceria has 
particles that are approximately 10-14 nm in diameter; PAA-
coated iron oxide nanoparticles are approximately 70-100 nm 60 
in diameter; Dextran-coated iron oxide nanoparticles (spheri-
cal) are approximately 60-120 nm in diameter; HBPE nano-
particles are approximately 100-130 nm in diameter. 
Apart from a near-infrared fluorophore that can achieve 
deep tissue imaging by circumventing auto-fluoresence in 65 
mammalian tissue, iron oxide nanoparticles were used for 
magnetic resonance imaging (MRI) with better spatial reso-
10 
lution and deeper penetration. Results indicate that the device 
exhibits near-infrared fluorescence emission, under physi-
ological or transient inflammatory conditions with low ROS 
concentrations. However, under prolonged exposure to ROS, 
simulating chronic inflammation, or in acidic and ROS-rich 
microenvironments fluorescence decreases significantly, due 
to the catalytic inactivation of cerium oxide nanoparticles and 
the fluorophore's susceptibility to ROS. Furthermore, we 
show that under elevated ROS, the iron oxide nanoparticles 
yield high T2 (spin-spin) relaxation times, which can be used 
as clinically applicable MRI tags for inflammation imaging. 
FIG. 1 is a conceptual diagram of an in vivo inflammation 
monitoring device having a first chamber 10 contains antioxi-
dant nanoparticles, such as nanoceria that functions as the 
reactive oxygen scavenging/sensing (ROS) chamber which is 
joined to a second chamber 20 contains nanoparticles that are 
fluorescent, magnetic or multimodal and is known herein as 
the monitoring chamber. Thus, construction of the inflamma-
tion monitoring device has two components; a first compo-
nent consisting of a nanoparticle or a nanocomposite with 
cerium oxide, a ROS-sensitive/scavenging probe, and second 
component consisting of imaging agents, fabricated through 
the utilization of material synthesis techniques and conjuga-
tion chemistry approaches. 
FIG. 2 is a schematic representation of the monitoring 
device's operating principle. The device consists of polymer-
coated cerium oxide nanoparticles in a first chamber 10 and 
fluorophore-containing nanoparticles in a second chamber 
20. The latter nanoparticles can be either fluorescent poly-
meric (i.e. hyperbranched polyester-HBPE-DiI) or polymer-
coated iron oxide nanoparticles (i.e. DiR-Dextran-IO). Each 
one of the device's chambers independently communicates 
with the aqueous environment through a semi-permeable 
membrane, freely allowing the diffusion of ROS from the 
exterior to the device's chambers. Note that there is no com-
munication between the two chambers. No communication 
means there is not any exchange of particles between the two 
chambers that are held in position by an adhesive or glue. 
Under conditions of no or mild inflammation a, the 
device's cerium oxide nanoparticle component (nanoceria) in 
chamber 11 scavenges the generated ROS, as ROS production 
is either or transient, leading to preservation of the device's 
fluorescence emission in chamber 22. However, under con-
ditions of chronic persistent inflammation b, nanoceria in 
chamber 12 does not have the ability to regenerate quickly 
enough, thus the excess ROS dim or switch off the device's 
fluorescence emission in chamber 24, due to the fluoro-
phore' s sensitivity to ROS. 
FIG. 3 is a graph of the time-dependent fluorescence of the 
imaging nanoparticles in the presence of hydrogen peroxide. 
One hundred percent fluorescence intensity in water 
decreases to approximately 60% fluorescence intensity in 
1400 minutes in the presence of hydrogen peroxide, a gen-
erator of reactive oxygen species (ROS). The photostability 
of the nanoparticles in water (control), is shown by the fluo-
rescence intensity remaining constant. In contrast, in the pres-
ence of hydrogen peroxide (H20 2 1 DD), the fluorescence 
emission of the HBPE-DiI nanoparticles decreases, due to the 
presence of ROS generated by H2 0 2 decomposition that oxi-
dizes the dye and therefore reduces its fluorescence intensity. 
FIG. 4 graphically depicts the decrease in the fluorescence 
emission of HBPE-DiI nanoparticles after 24 hours in the 
presence of hydrogen peroxide. Fluorescence emission spec-
troscopy indicates the stability of the fluorophore nanopar-
ticle (HBPE-DiI) in water and in the absence of ROS. At 
approximately 300 nm in wavelength, fluorescent intensity is 
measured at 1.0xl 07 cps. The fluorescence emission signifi-
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cantly decreases under elevated ROS concentrations due to 
decomposition of hydrogen peroxide (1 DD) and at approxi-
mately 300 nm wavelength fluorescence intensity is 6.0xl06 
cps. 
FIG. 5 is a graph of the time-dependent HBPE-DiI nano-
particle fluorescence emission in the presence of nanoceria 
and ROS in suspension. The graph demonstrates that nanoc-
eria facilitates the retention of the device's fluorescence emis-
sion (HBPE-DiI) in the presence of hydrogen peroxide (1 
DD), because nanoceria is able to scavenge the generated 
ROS therefore preserving the fluorescence emission of the 
dye. Over a period of approximately 1400 minutes, fluores-
cence intensity remains at approximately 95% of the initial 
fluorescence. Thus, nanoceria protects the fluorophore DiI 
containing component from ROS. 
FIG. 6 is a graph showing that nanoceria provides sustained 
protection from ROS to fluorescent nanoparticles. Fluores-
cence emission spectroscopy supports the hypothesis that the 
nanoceria component of the device would protect the fluores-
cence emission of the fluorophore(DiI)-containing compo-
nent, even in the presence of hydrogen peroxide (1 OM). 
12 
with or without nanoceria. However, ROS due to H2 0 2 does 
cause a decrease in the fluorescence emission ofDiR-Dex-IO 
when nanoceria is not present (FIG. SB); but in the presence 
of nanoceria, fluorescence is protected as nanoceria scav-
enges ROS at pH 7; the photobleaching effect of hydrogen 
peroxide is abrogated and fluorescence emission is retained 
(FIG. SD). Incubations for 24 hours were performed to check 
stability and long-term exposure to ROS. 
FIGS. 9A-9C show that a cerium oxide nanoparticle-based 
10 device with polymer coated, polyacrylic acid (PAA), nanoc-
eria protects the fluorescence emission of the DiI-Dex-IO 
nanoparticles from ROS after 24-hour exposure at physi-
ological H2 0 2 concentrations of 0.5 µM (FIG. 9A), 1.5 µM 
(FIG. 9B) and 3.0 µM (FIG. 9C) in solutions with a pH value 
15 of 7. Stated in another way, under physiological ROS levels 
([H20 2 ]=0-3 OM), nanoceria protects the fluorescence emis-
sion of the DiI-Dex-IO nanoparticles of an implantable thera-
peutic device. 
FIG. lOA shows that a cerium oxide nanoparticle-based 
20 device with polymer coated, polyacrylic acid (PAA), nanoc-
eria does not protect the fluorescence emission of the DiI-
Dex-IO nanoparticles from ROS after 24-hour exposure to 
H2 0 2 at a non-physiological pH value of 4, allowing imaging 
FIG. 7 is a graph of the time-dependent retention of the 
fluorescence emission of the HBPE-DiI fluorescent nanopar-
ticle by nanoceria after exposure to UV radiation. In the 
absence of nanoceria, the non-encapsulated fluorophore (DiI) 25 
rapidly loses its fluorescence emission. Encapsulation of the 
dye (HBPE-DiI) prolongs the fluorescence emission from the 
fluorophore, but gradually it decreases. Addition of nanoceria 
of ROS generation. 
FIG. lOB shows that a cerium oxide nanoparticle-based 
device with polymer coated, polyacrylic acid (PAA), nanoc-
eria does not protect the fluorescence emission of the DiI-
Dex-IO nanoparticles from ROS after 24-hour exposure 
under inflammatory conditions simulated by high levels of to the fluorescent nanoparticles protects fluorescence emis-
sion over prolonged exposure to UV radiation. The fluores-
cence intensity remains at 100% of the initial intensity for 
over 160 minutes. 
Collectively, FIGS. 3-7 demonstrate three important 
results of testing the two-chamber device in solution. First, in 
the presence of ROS, fluorescence emission from dyes, such 
as DiI, rapidly decrease making them suitable probes for ROS 
monitoring. Second, the addition of nanoceria results in pho-
toprotection of the fluorescence intensity of the dye, protect-
ing the fluorophore from ROS attacks. Third, nanoceria pro-
tects the fluorophore from direct damage and ROS generated 
during UV radiation. 
Photographic Evidence of Function of Polyacrylic Acid 
(PAA) Coated Nanoceria. 
The photographs were taken using a small animal imaging 
station (IVIS, Xenogen). However, these results can be 
obtained with other optical and fluorescence instrumentation, 
including other proprietary small animal imaging stations. 
FIG. SA shows that when there is no coating on nanoceria 
particles and no H2 0 2 is present, the fluorescence emission of 
the DiI-Dex-IO nanoparticles is constant/unaltered. 
In contrast, FIG. SB shows that a nanoparticle-based 
device with no coating on nanoceria and with 1 µM H2 0 2 
present in a solution with a pH value of 7 exhibits change in 
the fluorescence emission of its DiI-Dex-IO nanoparticles 
after 24-hour exposure to ROS; there is a significant loss in 
fluorescence emission from the device. 
FIG. SC shows that polymer-coated nanoceria (e.g., with 
polyacrylic acid (PAA) coating), does not affect the fluores-
cence emission of the DiI-Dex-IO nanoparticles. Most impor-
tantly as shown in FIG. SD, polymer-coated nanoceria pro-
tects the fluorescence emission of the DiI-Dex-IO 
nanoparticles from ROS after 24-hour exposure to H2 0 2 at 
pH 7; there is no change in fluorescence emission. 
30 ROS, generated by H20 2 . 
Thus, FIGS. lOA and lOB show that under conditions of 
elevated inflammation ([H20 2 ];;,;6 DD) or nanoceria's pH-
dependent catalytic inactivation (acidic pH, i.e., 4.0), the 
device's fluorescence emission from DiI-Dex-IO nanopar-
35 ticles decreases. It is worth mentioning that in vivo chronic 
inflammation is often associated with a decrease in the pH, 
thus it can contribute to decreased fluorescence emission. 
Hence, these data demonstrate that the device's "switch off' 
occurs specifically under non-physiological conditions, such 
40 as, high ROS and/or low pH, making the device suitable for in 
vivo imaging of inflanimation. 
In other words, during normal levels of inflammation the 
device will be responsive and nanoceria in the ROS-scaveng-
ing chamber will be able to scavenge ROS, preserving the 
45 monitoring chamber's fluorescence emission herein desig-
nated as the ON state. However, during chronic inflammation 
nanoceria will not be able to scavenge ROS and the device's 
performance will be affected, leading to decrease in fluores-
cence emission herein designated as the OFF state. Therefore, 
50 the decrease in fluorescence emission will be an indicator for 
the physician to take further action, minimizing inflammation 
and preventing systemic tissue damage. 
FIG. 11 is a graph of the change in fluorescence intensity 
under physiological and non-physiological conditions. The 
55 percentage decrease in the device's fluorescence emission 
(DiI-Dex-IO) upon polymer-coated nanoceria's ROS-scav-
enging inactivation was from approximately 100% intensity 
when H2 0 2 concentrations were 0.5 µM, 1.5 µMand 3.0 µM. 
The fluorescence emission intensity decreased to approxi-
60 mately 60% intensity when H20 2 concentrations were 1.0 µM 
at pH value 4. Fluoresence emission intensity decreased to 
approximately 30% when H2 0 2 concentrations were 6.0 µM, 
at conditions of elevated ROS levels. 
Thus, original photographs of the device (FIGS. SA, SC 
and SD) show that nanoceria does not affect DiR-Dex-IO 65 
fluorescence emission under physiological conditions, and 
the fluorescence of the DiR-Dex-IO is stable overtime, either 
FIG. 11 shows that in the presence of nanoceria, physi-
ological ROS levels do not affect the device's fluorescence. 
This indicates the specificity and sensitivity of the device. 
However, in the presence of nanoceria, elevated ROS levels 
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associated with aberrant inflammation cause decrease in fluo-
rescence emission (FIG.11). Thus, the device can be used for 
the monitoring of the inflammatory response. 
Also, in the presence of nanoceria and low pH, fluores-
cence emission decreases in the presence of ROS (FIG. 11). 
Hence, the device can be used for the monitoring of ROS 
generation during chemotherapy or gastrointestinal inflam-
mation, such as ulcerative colitis, inflammatory bowel dis-
ease, and Crohn's disease. 
14 
magnetic resonance imaging (MRI), by the monitoring cham-
ber and represents a second embodiment of the present inven-
tion. 
Multimodal monitoring of inflammation is useful when 
under elevated reactive oxygen species (ROS) levels or loss of 
nanoceria regeneration; the fluorescence emission and the 
magnetic resonance imaging of the nanocomposite changes 
and the ROS beacons facilitate tracking with the use of chemi-
luminescence, magnetic relaxation or X-ray contrast agents. 
Study of Factors that Reduce Fluoresence Emission of 10 
Fluorophores 
In FIG. 15, the ROS scavenging chamber 30 is positioned 
adjacent to multimodal monitoring chamber 40 and held in 
position by an adhesive or glue. In the two chamber device, 
there is no exchange of particles between the two chambers. 
Under conditions of no or mild inflanimation c, the device's 
To corroborate that the reduction in the fluorophore emis-
sion is due to ROS-induced damage and not due to the acidic 
pH, we performed the following experiments with the fluo-
rophore being in physiological (pH 7.5) and acidic (pH 4) 
levels. No nanoceria was used in these studies in order to 
ascribe the role of pH on fluorophore stability. 
FIG. 12 shows that the non-encapsulated fluorophore (DiI) 
has an almost identical absorbance curve at physiological (pH 
7.5) and acidic (pH 4) pH, indicating stability of the fluoro-
phore under both pH values. Ultraviolet (UV)-vis spectros-
copy reveals the fluorophore's (DiI) stability at physiological 
and acidic pH solutions, in the absence of hydrogen peroxide. 
Therefore, changes in fluorescence emission are due to expo-
sure to ROS and not due to the low pH per se. 
FIG. 13 is a graph of fluorescence intensity, and shows 
fluorescence emission stability of the non-encapsulated fluo-
rophore (DiI) at physiological (pH 7.5) and acidic (pH 4) 
values. Fluorescence emission spectroscopy indicates that the 
device's fluorophore emission (DiI) is pH-independent. No 
changes are observed in the emission profile between physi-
ological and acidic pH. 
Thus, the fluorophore's structural integrity is not affected 
by the pH, as indicated by the similar UV-vis spectra obtained 
at different pH levels. Also, the fluorescence emission profile 
of the fluorophore is not affected by pH levels, corroborating 
that the changes are caused after exposure to ROS. 
Factors that Affect Regeneration ofNanoceria Component. 
Next, it was determined if nanoceria in the ROS-scaveng-
ing chamber of the device has the ability to regenerate after 
exposure to ROS. Utilizing X-ray photoelectron spectros-
copy (XPS), we deduced the valence state of the nanoceria's 
cerium (Ce+3 /Ce+4 ) is measured at different pH levels and 
ROS levels. Proof of regeneration is shown when Ce+3 ions 
are present at a concentration level above approximately 55% 
and Ce+4 ions are present in a concentration level greater than 
approximately 40% of the total cerium ions. 
15 cerium oxide nanoparticle component (nanoceria) in cham-
ber 31 scavenges the generated ROS, as ROS production is 
either nominal or transient, leading to preservation of the 
device's fluorescence emission in chamber 42. However, 
under conditions of chronic persistent inflammation d, nano-
20 ceria in chamber 32 does not have the ability to regenerate 
quickly enough, thus the excess ROS dim or switch off the 
device's fluorescence emission in chamber 44, due to the 
fluorophore's sensitivity to ROS. However, due to the use of 
iron oxide nanoparticles in the monitoring chamber 40 and 
25 the benefits of magnetic resonance imaging (MRI), there is an 
increased MRI signal from the monitoring chamber 44. 
Iron oxide nanoparticles are selected because of the wide 
clinical use in tomographic image acquisitions, and excellent 
deep tissue resolution and penetration. DiR is used, which is 
30 a near-infrared fluorophore tht can be used for optical imag-
ing avoiding tissue autofluorescence. The iron oxide particles 
were also dextran coated (Dex-IO), as they are widely used in 
the clinic as MRI contrast agents. Hence, encapsulated DiR in 
Dex-IO nanoparticles (DiR-Dex-IO) are proven to have a 
35 dual probe for potentially clinical in vivo inflanimationmoni-
toring. 
FIG.16A shows that in the absence ofnanoceria, themul-
timodal DiR-Dex-IO nanoparticles can sense ROS generated 
by H2 0 2 (1.0 µM), after 24-hour exposure to H2 0 2 in pH 7 
40 (physiological pH) via changes in fluorescence and T2 relax-
ation times (T2,n=165 ms, T2fin=280 ms). FIG. 16B shows 
that in the presence ofnanoceria, the multimodal DiR-Dex-
IO nanoparticles can differentiate physiological ROS levels 
generated by H20 2 and the ROS beacons retain their fluores-
45 cence emission intensity with a small change in the T2 relax-
ation times (T2,n = 165 ms, T2fin =220 ms). Thus, it was deter-
mined that a physician using the nanocomposite device will 
not receive a false positive signal when ROS levels and pH are 
physiological. 
In the presence of nanoceria, DiR-Dex-IO nanoparticles 
retain near-infrared fluorescence and T2 relaxation does not 
change significantly, under exposure to ROS. 
FIG. 14 is a chart showing the percentage of each valence 50 
state of the cerium element in the polymer-coated nanoceria 
componentatpH7;pH7and1.0 µMH 2 0 2 ; pH4and1.0 µM 
H2 0 2 ; pH 7 and 6.0 µM H2 0 2 . In the absence of nanoceria, exposure to ROS leads to a 
decrease in the DiR-Dex-IO nanoparticle fluorescence where 
55 the T2 relaxation increases. This indicates that the device can 
XPS analysis indicates that at low ROS concentrations, 
such as 1 µM H20 2 , the device's nanoceria has the ability to 
regenerate. At acidic Ph, such as pH 4, or high inflanimatory 
conditions (high ROS), such as 6 µM H2 0 2 , nanoceria loses 
its autoregenerative property, leading to a decrease in the 
device's fluorescence emission, as the DiI-Dex-IO fluoro-
phore is susceptible to ROS attacks. 
Multi-Modal DiR-Dex-IO Nanoparticle for a NIR-Fluo-
rescent/MRI Monitoring Chamber. 
60 
Multimodal monitoring of inflanimation through a device, 
consisting of a ROS-scavenging chamber 30 with nanoceria 
and a multimodal monitoring chamber 40 with DiR-doped 65 
dextran-coated iron oxide nanoparticles is shown in FIG. 15. 
The use of a multimodal DiR-Dex-IO nanoparticle allows 
be used in the clinic for inflammation monitoring with MRI 
and optical imaging methods. The changes in the T2 relax-
ation times upon exposure to ROS are attributed to nanopar-
ticle clustering. 
To elucidate the changes in the T2 relaxation times, 
Dynamic Light Scattering (DLS) was employed. Results 
indicate that in the absence of hydrogen peroxide the nano-
particles' average diameter size was 135 nm (FIG. 17A). 
However, under elevated ROS levels generated by H2 0 2 and 
without nanoceria in the solution to scavenge them, the nano-
particles' average size significantly increased, demonstrating 
micron-size cluster aggregation with an average particle size 
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of2860 run in diameter. (FIG. 17B). Hence, this phenomenon 
justifies the prominent changes in the relaxation times under 
inflammatory conditions with elevated ROS and no nanoc-
eria. Finally, we assessed the multimodal DiR-Dex-IO nano-
particles' sensitivity towards ROS, observing that even at low 
concentrations of H2 0 2 the nanoparticles could induce 
prominent shifts in the T2 relaxation times (FIG. 18) which 
can be detected by MRI. This indicates that these nanopar-
ticles are sensitive ROS imaging probes, thus even slightly 
aberrant concentrations of ROS could "tum" the nanopar- 10 
ticles' imaging switch and change the T2 relaxation time. 
16 
In FIGS. 20 and21, it is demonstrated that a single chamber 
device of the present invention distinguishes between physi-
ological and inflanmiatory conditions. Overall, in the absence 
of ROS or at moderate ROS levels associated with transient 
and mild inflammation, the nanoceria in the device is able to 
scavenge ROS. As a result, fluorescence emission is retained 
and the T2 relaxation times are comparable to those observed 
under normal physiological conditions. 
However, at high levels of ROS associated with chronic 
and acute inflanmiation or under non-physiological condi-
tions manifested with decreases in the pH levels, the fluores-
cence emission of the device significantly lowers and the T2 
relaxation times drastically increase. Thus, under acute con-
ditions, nanoceria carmot scavenge ROS, changing the 
FIG.19 is a conceptual diagram of the in vivo inflanmiation 
monitoring device of the present invention having a single 
chamber which is a second embodiment of the device of the 
present invention. The first embodiment has two chambers 
that are not communicating; a first chamber for the ROS 
scavenger and a second chamber for monitoring clinical con-
ditions. The design of the first embodiment is to minimize 
potential fluorophore quenching by nanoceria. However, pre-
liminary results with a nanocomposite consisting of nanoc-
eria and fluorophore-containing nanoparticles indicated no 
quenching or photostability issues. Therefore the second 
embodiment is a single chamber device containing the 
reagents, such as nanoceria and DiR-IO-Dex or a nanocom-
posite. 
15 device's fluorescence and MRI signatures and signaling 
therapeutic intervention. 
In summary, the present invention provides a therapeutic 
device which is designed to have applications in a broad range 
of ailments with a pro-inflanmiatory component, such as 
20 Crohn' s disease, inflammatory bowel disease, ulcerative coli-
tis, cystic fibrosis, sepsis, cardiovascular disease, arthritis, 
multiple sclerosis, and Alzheimer's. Furthermore, the use of 
ROS agents in cancer chemotherapy is reported in several 
representative publications, such as, Chung, H. Y., et al., 
25 "Molecular inflammation: underpinnings of aging and age-
related diseases." Ageing Res Rev, 2009. 8(1): 18-30 and 
Shacter, E., et al., in "Oxidative stress interferes with cancer 
chemotherapy: inhibition of lymphoma cell apoptosis and 
The reactive oxygen species (ROS) scavenger particles 50 
and the imaging agent particles 60 can be interspersed in one 
chamber. If there are no inflammatory conditions, the nano-
ceria particles regenerate and fluorescence emission of the 
imaging agent occurs. In the presence of persistent inflam- 30 
matory conditions, the nanoceria particles do not regenerate 
and the fluorescence emission of the imaging agent is extin-
guished. 
phagocytosis" Blood, 2000. 96(1): p. 307-13. 
Thus, the two-chamber or single chamber device of the 
present invention can be utilized as an implant in cancer 
therapeutic regimes. Also, patients with transplants or pros-
thetic devices may utilize the cerium-oxide-nanoparticle-
based device for the in vivo monitoring of the post-operative Dimensions of the device provided by the present invention 
are given only as an illustration, not as a limitation. A mac-
roscale device is approximately 2 centimeters (cm) in length 
and approximately 0.4 cm in diameter. A miniature device is 
approximately 2-4 millimeters (mm) in length and approxi-
mately 1 mm in diameter. 
35 inflammatory response. 
The device of the present invention can be miniaturized and 
integrated in a prosthetic organ. Moreover, as the nanopar-
ticles' cavity can host a plethora of probes, the device may be 
modified in order to be specific to certain ROS species, such 
40 as hydroxyl, superoxide, nitroxyl, peroxide and other free 
radicals, while having multimodality through the presence of 
fluorescent, chemiluminescent, magnetic and X-ray agents. 
Also, the cerium oxide nanoparticles protect the therapeutic 
device's fluorophore against UV radiation, hence making the 
FIG. 20 is a side-view of the fluorescence image of the 
single-chamber device consisting of polymer-coated, poly-
acrylic acid (PAA) nanoceria and DiR-Dex-IO nanoparticles 
after 24-hour-long incubation at physiological conditions. In 
FIG. 20, image 1 is the control that shows bright fluorescence 
intensity with no ROS present, i.e. no H20 2 at pH 7. At a 
physiological H2 0 2 concentration, image 2 also shows bright 
fluorescence intensity when the device is used in an environ-
ment with 1 µM H2 0 2 at pH 7 .At a non-physiological inflam-
matory H20 2 concentration, image 3 shows a diminished 
fluorescence intensity in a range of approximate 0.9-1.0xl 05 50 
in an enviromnent with 6 µM H20 2 at pH 7, and at a non-
physiological chronic inflammatory level H2 0 2 concentra-
tion and non-physiological pH (6 µM H2 0 2 , pH 4), image 4 
shows a greatly decreased fluorescence intensity in the range 
45 device suitable for clinical applications, such as chemo-
therapy, and industry-related activities, including, but not 
limited to prosthesis, post transplant operations, UV protec-
tion, chemical synthesis, pharmaceutical research and devel-
opment, basic and clinical research. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
of approximately 0.1-0.3xl05 . 55 ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
FIG. 21 is a top-view of an MRI image of the single-
chamber consisting of polymer-coated, polyacrylic acid 
(PAA) nanoceria and DiR-Dex-IO nanoparticles after 
24-hour-long incubation at physiological conditions. In FIG. 
21, Image 5 is of a T2 relaxation time when there are no ROS 60 
i.e. no H20 2 at pH 7. Image 6 shows T2 relaxation time in the 
presence of 1 µM H2 0 2 , at pH 7. T2 relaxation times are 
shown in non-physiological conditions in Image 7 with 6 µM 
H2 0 2 at pH 7 and in Image 8 with 6 µM H20 2 at pH 4 which 
represents the most severe condition with high ROS and low 65 
pH. The T2 relaxation times increase as the physiological 
conditions deviate from normal conditions. 
We claim: 
1. A nanocomposite system encapsulating nanoparticle 
elements not present in a living body for detection of reactive 
oxygen species, said nanocomposite system comprising a 
miniature device in a form of a chamber containing therein 
nanocomposite including a reactive oxygen species (ROS)-
scavenging nanoparticle component and a reporting nanopar-
ticle component that comprises nanoparticles including one 
or more imaging agent, and having an exterior semi-perme-
able membrane encapsulating both nanoparticle components 
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within the chamber; said ROS-scavenging nanoparticle com-
ponent comprising polymer coated cerium oxide nanopar-
ticles, and said nanocomposite comprising a multimodal 
nanocomposite formed by chemical conjugation of the poly-
mer coated cerium oxide nanoparticles and the reporting 
nanoparticle component; said (ROS)-scavenging nanopar-
ticle component and said reporting nanoparticle component 
communicating with an aqueous environment outside of said 
chamber through the semi-permeable membrane that permits 
diffusion of the reactive oxygen species therethrough; said 10 
ROS-scavenging nanoparticle component of the nanocom-
posite protecting the reporting nanoparticle component from 
the reactive oxygen species under the normal physiological 
condition; said reporting nanoparticle component in the 
chamber incurring an imaging detectable change in the pres- 15 
ence of an elevated non-physiological level of the reactive 
oxygen species associated with an aberrant clinical condition ther~by indicating the presence of an elevated non-physi~ 
olog1cal level of the reactive oxygen species. 
2. The system of claim 1, wherein said multimodal nano- 20 
com~osite. is formed bl'. conjugation of propargylated poly-
acryhc acid coated cenum oxide nanoparticles and azide-
carrying indotricarbocyanine polyacrylic acid-coated iron 
oxide (DiR-PAA-IO). 
3. The system of claim 1, wherein said multimodal nano- 25 
com~osit~ is formed by carbodiimide conjugation of poly-
acryhc acid coated cerium oxide nanoparticles and aminated 
indotricarbocyanine dextran-coated iron oxide (DiR-Dex-
IO). 
4. The system of claim 1, wherein the miniature device is 30 
approximately 2 to 4 millimeters (mm) in length and approxi-
mately 1 mm in diameter. 
5. The system of claim 1, wherein said polymer-coated 
cerium oxide nanoparticles are coated with dextran or poly-
acrylic acid. 
6. 1:he system of claim 1, wherein said imaging agent 35 
compnses at least one of a fluorophore capable of fluores-
c~nce emission, a chemiluminescent agent, a magnetic relax-
at10n agent, and an X-ray contrast agent. 
7. The system of claim 6, wherein said imaging agent 
comprises a fluorophore selected from at least one of octode- 40 
~yl ii:docarbocy.anine (Dil), indodicarbocyanine (DiD), 
mdotncarbocyanme (DiR), cyanine 5.5 (Cy5.5), and 
indocyanine green (ICG). 
. 8. The system of claim 6, wherein the reporting nanopar-
t1cle component comprises nanoparticles of at least one of 45 
iron oxide, bismuth, europium, gadolinium and chelates 
thereof. 
9. The system of claim 6, wherein the nanoparticles includ-
ing one or more imaging agent are coated with at least one 
polymer selected from dextran, polyacrylic acid, hyper-
branched polyester, poly-lactic-co-glycolic acid, and mix-
50 
tures thereof. 
10. A nanocomposite system encapsulating nanoparticle 
elements not present in a living body for detection of reactive 
o~y?en speci~s, ~aid nanocomposite system comprising a 
m1mature device m a form of a chamber containing therein 55 
nanocomposite including polymer-coated cerium oxide 
nanoparticles and imaging nanoparticles and having an exte-
rior semi-permeable membrane encapsulating the nanopar-
ticles within the chamber; said polymer-coated cerium oxide 
n~oparticles and said ii_naging nanoparticles communicating 60 
with an aqueous environment outside of said chamber 
through the semi-permeable membrane that permits diffusion 
of the reactive oxygen species therethrough; said polymer-
coa~ed ceri~ o~ide nanoparticles of the nanocomposite pro-
tect11:1g the 1magmg nanoparticles from the reactive oxygen 
species under the normal physiological condition; said imag-
18 
ing nanopart!cles in the chamber incurring an imaging detect-
able change m th~ presence of an elevated non-physiological 
level of the reactive oxygen species associated with an aber-
rant clinical condition, thereby indicating the presence of an 
e!evated non-physiological level of the reactive oxygen spe-
cies. 
11. The system of claim 10, wherein said nanocomposite 
c.omprises multimodal nanocomposite formed by conjuga-
t10n of propargylated polyacrylic acid coated cerium oxide 
nanoparticles and azide-carrying indotricarbocyanine poly-
acrylic acid-coated iron oxide (DiR-PAA-IO). 
. 12. The system ?f claim 10, wherein the imaging nanopar-
t1cles are nanopart1cles of at least one of iron oxide bismuth 
europium, gadolinium and chelates thereof. ' ' 
13. The system of claim 10, wherein the imaging nanopar-
ticles are coated with at least one polymer selected from 
dextran, polyacrylic acid, hyper-branched polyester, poly-
lactic-co-glycolic acid, and mixtures thereof. 
. 14. The system of claim 10, wherein the imaging nanopar-
t1cl~s are polyme~-coat.ed nanoparticles ofiron oxide for mag-
netic. resonance 1magmg detection of the reactive oxygen 
species, or polymer-coated nanoparticles of iron oxide con-
taining a fluorophore for magnetic resonance imaging and 
fl?orescence imaging detections of the reactive oxygen spe-
cies. 
15. '.fhe syst~m of claim 10, wherein said nanocomposite 
compnses multJmodal nanocomposite formed by carbodiim-
ide conjugation of polyacrylic acid coated cerium oxide 
nanoparticles and aminated indotricarbocyanine dextran-
coated iron oxide (DiR-Dex-IO). 
16. The system of claim 15, wherein the miniature device is 
approximately 2 to 4 millimeters (mm) in length and approxi-
mately 1 mm in diameter. 
17. The system of claim 15, wherein the polymer-coated 
cerium oxide nanoparticles are coated with dextran or poly-
acrylic acid. 
. 18. !he system of claim 10, wherein the imaging nanopar-
t1cles mclude one or more imaging agent comprising at least 
one of a fluorophore capable of fluorescence emission a 
chemiluminescent agent, a magnetic relaxation agent, and, an 
X-ray contrast agent. 
19. !he system of claim 18, wherein the imaging agent 
compnses a fluorophore selected from at least one of octode-
~yl ii:docarbocy.anine ~Dil), indodicarbocyanine (DiD), 
mdotncarbocyanme (D1R), cyanine 5.5 (Cy5.5), and 
indocyanine green (ICG). 
20. A nanocomposite system encapsulating nanoparticle 
elements not present in a living body for detection of reactive 
o~y?en speci~s, ~aid nanocomposite system comprising a 
mmiature device m a form of a chamber containing therein 
nanocomposite comprising polymer-coated cerium oxide 
nanoparticles .and polymer-coated nanoparticles containing 
one or more 1magmg agent, and having an exterior semi-
permeable membrane encapsulating the nanoparticles within 
t~e chambe7; .said polymer-coated cerium oxide nanopar-
t1cles and said 1magmg nanoparticles communicating with an 
aqueous environment outside of said chamber through the 
semi-permeable membrane that permits diffusion of the reac-
tive oxygen species therethrough; said polymer-coated 
ceri'.-lm o:cide nanopai:ticles of the nanocomposite protecting 
the 1magmg nanopart1cles from the reactive oxygen species 
und~rthe i:iormal physiological condition; said imaging nano-
part1cles m the chamber incurring an imaging detectable 
change in the presence of an elevated non-physiological level 
of the reactive oxygen species associated with an aberrant 
clinical condition, thereby indicating the presence of an 
e!evated non-physiological level of the reactive oxygen spe-
cies. 
* * * * * 
